Reply to Office Action of December 29, 2005

AMENDMENTS TO THE SPECIFICATION

Docket No.: 20052/1200520-US4

Please replace the first full paragraph beginning on p. 3, ll. 10-17, with the following rewritten paragraph:

Accordingly, the methods of the invention are particularly useful for inducing T cell tolerance to a donor tissue or organ in a recipient of the tissue or organ. The methods involve administering to a transplant recipient: 1) an allogeneic or xenogeneic cell which expresses at least one donor antigen and which has a ligand on a cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector functions; and 2) an antagonist of the molecule on the surface of the recipient T cell which mediates contact-dependent helper effector functions. The antagonist inhibits an interaction between the molecule on the T cell and it's its ligand on the allogeneic or xenogeneic cell.

Please replace the first full paragraph beginning on p. 5, ll. 10-27, with the following rewritten paragraph:

In addition to the allogeneic or xenogeneic cell, an antagonist of a molecule on T cells which mediates contact dependent helper effector functions is administered to the recipient as part of the tolerization regimen. As defined herein, a molecule or receptor which mediates contact dependent helper effector functions is one which is expressed on a Th cell and interacts with a ligand on an effector cell (e.g., a B cell), wherein the interaction of the molecule with it's its ligand is necessary for generation of an effector cell response (e.g., B cell activation). In addition to being involved in effector cell responses, it has now been found that such a molecule or receptor is involved in the response of the T cell to antigen. Preferably, the molecule on a T cell which mediates contact-dependent helper effector function is gp39. Accordingly, in preferred embodiments, the methods of the invention involve administering to a transplant recipient an allogeneic or xenogeneic cell and a gp39 antagonist. Activation of recipient T cells by the allogeneic or xenogeneic cell involves an interaction between gp39 on recipient T cells and a gp39 ligand on the allogeneic or xenogeneic cell. By inhibiting this interaction with a gp39 antagonist, the T cells of the recipient are not activated by the donor antigens expressed by the allogeneic or xenogeneic cell but rather become {W:20052\1200520us4\00630246.DOC *20052\1200520US4*}

Application No. 09/888,639 Amendment dated March 24, 2006 Reply to Office Action of December 29, 2005

of the donor graft.

Docket No.: 20052/1200520-US4

tolerized to the donor antigens. Induction of tolerance to donor antigens in the recipient thus

enables successful transplantation of the donor tissue or organ without immune-mediated rejection